Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 362

1.

Early increase of CSF sTREM2 in Alzheimer's disease is associated with tau related-neurodegeneration but not with amyloid-β pathology.

Suárez-Calvet M, Morenas-Rodríguez E, Kleinberger G, Schlepckow K, Araque Caballero MÁ, Franzmeier N, Capell A, Fellerer K, Nuscher B, Eren E, Levin J, Deming Y, Piccio L, Karch CM, Cruchaga C, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Alzheimer’s Disease Neuroimaging Initiative.

Mol Neurodegener. 2019 Jan 10;14(1):1. doi: 10.1186/s13024-018-0301-5.

2.

Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE.

Parhizkar S, Arzberger T, Brendel M, Kleinberger G, Deussing M, Focke C, Nuscher B, Xiong M, Ghasemigharagoz A, Katzmarski N, Krasemann S, Lichtenthaler SF, Müller SA, Colombo A, Monasor LS, Tahirovic S, Herms J, Willem M, Pettkus N, Butovsky O, Bartenstein P, Edbauer D, Rominger A, Ertürk A, Grathwohl SA, Neher JJ, Holtzman DM, Meyer-Luehmann M, Haass C.

Nat Neurosci. 2019 Feb;22(2):191-204. doi: 10.1038/s41593-018-0296-9. Epub 2019 Jan 7.

PMID:
30617257
3.

CSF progranulin increases in the course of Alzheimer's disease and is associated with sTREM2, neurodegeneration and cognitive decline.

Suárez-Calvet M, Capell A, Araque Caballero MÁ, Morenas-Rodríguez E, Fellerer K, Franzmeier N, Kleinberger G, Eren E, Deming Y, Piccio L, Karch CM, Cruchaga C, Paumier K, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Jucker M, Masters CL, Rossor MN, Ringman JM, Shaw LM, Trojanowski JQ, Weiner M, Ewers M, Haass C; Dominantly Inherited Alzheimer Network; Alzheimer's Disease Neuroimaging Initiative.

EMBO Mol Med. 2018 Dec;10(12). pii: e9712. doi: 10.15252/emmm.201809712.

4.

Efficacy of chronic BACE1 inhibition in PS2APP mice depends on the regional Aβ deposition rate and plaque burden at treatment initiation.

Brendel M, Jaworska A, Overhoff F, Blume T, Probst F, Gildehaus FJ, Bartenstein P, Haass C, Bohrmann B, Herms J, Willem M, Rominger A.

Theranostics. 2018 Sep 9;8(18):4957-4968. doi: 10.7150/thno.27868. eCollection 2018.

5.

Early and longitudinal microglial activation but not amyloid accumulation predict cognitive outcome in PS2APP mice.

Focke C, Blume T, Zott B, Shi Y, Deussing M, Peters F, Schmidt C, Kleinberger G, Lindner S, Gildehaus FJ, Beyer L, von Ungern-Sternberg B, Bartenstein P, Ozmen L, Baumann K, Dorostkar MM, Haass C, Adelsberger H, Herms J, Rominger A, Brendel M.

J Nucl Med. 2018 Sep 27. pii: jnumed.118.217703. doi: 10.2967/jnumed.118.217703. [Epub ahead of print]

PMID:
30262517
6.

White matter diffusion alterations precede symptom onset in autosomal dominant Alzheimer's disease.

Araque Caballero MÁ, Suárez-Calvet M, Duering M, Franzmeier N, Benzinger T, Fagan AM, Bateman RJ, Jack CR, Levin J, Dichgans M, Jucker M, Karch C, Masters CL, Morris JC, Weiner M, Rossor M, Fox NC, Lee JH, Salloway S, Danek A, Goate A, Yakushev I, Hassenstab J, Schofield PR, Haass C, Ewers M.

Brain. 2018 Oct 1;141(10):3065-3080. doi: 10.1093/brain/awy229.

7.

The Trem2 R47H Alzheimer's risk variant impairs splicing and reduces Trem2 mRNA and protein in mice but not in humans.

Xiang X, Piers TM, Wefers B, Zhu K, Mallach A, Brunner B, Kleinberger G, Song W, Colonna M, Herms J, Wurst W, Pocock JM, Haass C.

Mol Neurodegener. 2018 Sep 6;13(1):49. doi: 10.1186/s13024-018-0280-6.

8.

Early lysosomal maturation deficits in microglia triggers enhanced lysosomal activity in other brain cells of progranulin knockout mice.

Götzl JK, Colombo AV, Fellerer K, Reifschneider A, Werner G, Tahirovic S, Haass C, Capell A.

Mol Neurodegener. 2018 Sep 4;13(1):48. doi: 10.1186/s13024-018-0281-5.

9.

Nasal high-frequency oscillatory ventilation and CO2 removal: A randomized controlled crossover trial.

Bottino R, Pontiggia F, Ricci C, Gambacorta A, Paladini A, Chijenas V, Liubsys A, Navikiene J, Pliauckiene A, Mercadante D, Colnaghi M, Tana M, Tirone C, Lio A, Aurilia C, Pastorino R, Purcaro V, Maffei G, Liberatore P, Consigli C, Haass C, Lista G, Agosti M, Mosca F, Vento G.

Pediatr Pulmonol. 2018 Sep;53(9):1245-1251. doi: 10.1002/ppul.24120. Epub 2018 Jul 12.

PMID:
29999596
10.

Comparison of 18F-T807 and 18F-THK5117 PET in a Mouse Model of Tau Pathology.

Brendel M, Yousefi BH, Blume T, Herz M, Focke C, Deussing M, Peters F, Lindner S, von Ungern-Sternberg B, Drzezga A, Bartenstein P, Haass C, Okamura N, Herms J, Yakushev I, Rominger A.

Front Aging Neurosci. 2018 Jun 7;10:174. doi: 10.3389/fnagi.2018.00174. eCollection 2018.

11.

Diffusible, highly bioactive oligomers represent a critical minority of soluble Aβ in Alzheimer's disease brain.

Hong W, Wang Z, Liu W, O'Malley TT, Jin M, Willem M, Haass C, Frosch MP, Walsh DM.

Acta Neuropathol. 2018 Jul;136(1):19-40. doi: 10.1007/s00401-018-1846-7. Epub 2018 Apr 23.

PMID:
29687257
12.

Left frontal hub connectivity delays cognitive impairment in autosomal-dominant and sporadic Alzheimer's disease.

Franzmeier N, Düzel E, Jessen F, Buerger K, Levin J, Duering M, Dichgans M, Haass C, Suárez-Calvet M, Fagan AM, Paumier K, Benzinger T, Masters CL, Morris JC, Perneczky R, Janowitz D, Catak C, Wolfsgruber S, Wagner M, Teipel S, Kilimann I, Ramirez A, Rossor M, Jucker M, Chhatwal J, Spottke A, Boecker H, Brosseron F, Falkai P, Fliessbach K, Heneka MT, Laske C, Nestor P, Peters O, Fuentes M, Menne F, Priller J, Spruth EJ, Franke C, Schneider A, Kofler B, Westerteicher C, Speck O, Wiltfang J, Bartels C, Araque Caballero MÁ, Metzger C, Bittner D, Weiner M, Lee JH, Salloway S, Danek A, Goate A, Schofield PR, Bateman RJ, Ewers M.

Brain. 2018 Apr 1;141(4):1186-1200. doi: 10.1093/brain/awy008.

13.

The TREM2-APOE Pathway Drives the Transcriptional Phenotype of Dysfunctional Microglia in Neurodegenerative Diseases.

Krasemann S, Madore C, Cialic R, Baufeld C, Calcagno N, El Fatimy R, Beckers L, O'Loughlin E, Xu Y, Fanek Z, Greco DJ, Smith ST, Tweet G, Humulock Z, Zrzavy T, Conde-Sanroman P, Gacias M, Weng Z, Chen H, Tjon E, Mazaheri F, Hartmann K, Madi A, Ulrich JD, Glatzel M, Worthmann A, Heeren J, Budnik B, Lemere C, Ikezu T, Heppner FL, Litvak V, Holtzman DM, Lassmann H, Weiner HL, Ochando J, Haass C, Butovsky O.

Immunity. 2017 Sep 19;47(3):566-581.e9. doi: 10.1016/j.immuni.2017.08.008.

14.

An Alzheimer-associated TREM2 variant occurs at the ADAM cleavage site and affects shedding and phagocytic function.

Schlepckow K, Kleinberger G, Fukumori A, Feederle R, Lichtenthaler SF, Steiner H, Haass C.

EMBO Mol Med. 2017 Oct;9(10):1356-1365. doi: 10.15252/emmm.201707672.

15.

The wide genetic landscape of clinical frontotemporal dementia: systematic combined sequencing of 121 consecutive subjects.

Blauwendraat C, Wilke C, Simón-Sánchez J, Jansen IE, Reifschneider A, Capell A, Haass C, Castillo-Lizardo M, Biskup S, Maetzler W, Rizzu P, Heutink P, Synofzik M.

Genet Med. 2018 Feb;20(2):240-249. doi: 10.1038/gim.2017.102. Epub 2017 Jul 27.

16.

Time Courses of Cortical Glucose Metabolism and Microglial Activity Across the Life Span of Wild-Type Mice: A PET Study.

Brendel M, Focke C, Blume T, Peters F, Deussing M, Probst F, Jaworska A, Overhoff F, Albert N, Lindner S, von Ungern-Sternberg B, Bartenstein P, Haass C, Kleinberger G, Herms J, Rominger A.

J Nucl Med. 2017 Dec;58(12):1984-1990. doi: 10.2967/jnumed.117.195107. Epub 2017 Jul 13.

17.

The FTD-like syndrome causing TREM2 T66M mutation impairs microglia function, brain perfusion, and glucose metabolism.

Kleinberger G, Brendel M, Mracsko E, Wefers B, Groeneweg L, Xiang X, Focke C, Deußing M, Suárez-Calvet M, Mazaheri F, Parhizkar S, Pettkus N, Wurst W, Feederle R, Bartenstein P, Mueggler T, Arzberger T, Knuesel I, Rominger A, Haass C.

EMBO J. 2017 Jul 3;36(13):1837-1853. doi: 10.15252/embj.201796516. Epub 2017 May 30.

18.

TREM2 deficiency impairs chemotaxis and microglial responses to neuronal injury.

Mazaheri F, Snaidero N, Kleinberger G, Madore C, Daria A, Werner G, Krasemann S, Capell A, Trümbach D, Wurst W, Brunner B, Bultmann S, Tahirovic S, Kerschensteiner M, Misgeld T, Butovsky O, Haass C.

EMBO Rep. 2017 Jul;18(7):1186-1198. doi: 10.15252/embr.201743922. Epub 2017 May 8.

19.

Heterogeneous ribonuclear protein A3 (hnRNP A3) is present in dipeptide repeat protein containing inclusions in Frontotemporal Lobar Degeneration and Motor Neurone disease associated with expansions in C9orf72 gene.

Davidson YS, Flood L, Robinson AC, Nihei Y, Mori K, Rollinson S, Richardson A, Benson BC, Jones M, Snowden JS, Pickering-Brown S, Haass C, Lashley T, Mann DMA.

Acta Neuropathol Commun. 2017 Apr 21;5(1):31. doi: 10.1186/s40478-017-0437-5.

20.

Antibodies inhibit transmission and aggregation of C9orf72 poly-GA dipeptide repeat proteins.

Zhou Q, Lehmer C, Michaelsen M, Mori K, Alterauge D, Baumjohann D, Schludi MH, Greiling J, Farny D, Flatley A, Feederle R, May S, Schreiber F, Arzberger T, Kuhm C, Klopstock T, Hermann A, Haass C, Edbauer D.

EMBO Mol Med. 2017 May;9(5):687-702. doi: 10.15252/emmm.201607054.

21.

Motor neuron intrinsic and extrinsic mechanisms contribute to the pathogenesis of FUS-associated amyotrophic lateral sclerosis.

Scekic-Zahirovic J, Oussini HE, Mersmann S, Drenner K, Wagner M, Sun Y, Allmeroth K, Dieterlé S, Sinniger J, Dirrig-Grosch S, René F, Dormann D, Haass C, Ludolph AC, Lagier-Tourenne C, Storkebaum E, Dupuis L.

Acta Neuropathol. 2017 Jun;133(6):887-906. doi: 10.1007/s00401-017-1687-9. Epub 2017 Feb 28.

22.

Increase of TREM2 during Aging of an Alzheimer's Disease Mouse Model Is Paralleled by Microglial Activation and Amyloidosis.

Brendel M, Kleinberger G, Probst F, Jaworska A, Overhoff F, Blume T, Albert NL, Carlsen J, Lindner S, Gildehaus FJ, Ozmen L, Suárez-Calvet M, Bartenstein P, Baumann K, Ewers M, Herms J, Haass C, Rominger A.

Front Aging Neurosci. 2017 Jan 31;9:8. doi: 10.3389/fnagi.2017.00008. eCollection 2017.

23.

The APOE ε4 genotype modulates CSF YKL-40 levels and their structural brain correlates in the continuum of Alzheimer's disease but not those of sTREM2.

Gispert JD, Monté GC, Suárez-Calvet M, Falcon C, Tucholka A, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement (Amst). 2016 Dec 22;6:50-59. doi: 10.1016/j.dadm.2016.12.002. eCollection 2017.

24.

Beta-Site Amyloid Precursor Protein Cleaving Enzyme 1 Inhibition Impairs Synaptic Plasticity via Seizure Protein 6.

Zhu K, Xiang X, Filser S, Marinković P, Dorostkar MM, Crux S, Neumann U, Shimshek DR, Rammes G, Haass C, Lichtenthaler SF, Gunnersen JM, Herms J.

Biol Psychiatry. 2018 Mar 1;83(5):428-437. doi: 10.1016/j.biopsych.2016.12.023. Epub 2016 Dec 26.

25.

Glycine-alanine dipeptide repeat protein contributes to toxicity in a zebrafish model of C9orf72 associated neurodegeneration.

Ohki Y, Wenninger-Weinzierl A, Hruscha A, Asakawa K, Kawakami K, Haass C, Edbauer D, Schmid B.

Mol Neurodegener. 2017 Jan 14;12(1):6. doi: 10.1186/s13024-016-0146-8.

26.

Young microglia restore amyloid plaque clearance of aged microglia.

Daria A, Colombo A, Llovera G, Hampel H, Willem M, Liesz A, Haass C, Tahirovic S.

EMBO J. 2017 Mar 1;36(5):583-603. doi: 10.15252/embj.201694591. Epub 2016 Dec 21.

27.

Early changes in CSF sTREM2 in dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury.

Suárez-Calvet M, Araque Caballero MÁ, Kleinberger G, Bateman RJ, Fagan AM, Morris JC, Levin J, Danek A, Ewers M, Haass C; Dominantly Inherited Alzheimer Network.

Sci Transl Med. 2016 Dec 14;8(369):369ra178.

28.

Frontotemporal dementia: from molecular mechanisms to therapy.

Haass C, Neumann M.

J Neurochem. 2016 Aug;138 Suppl 1:3-5. doi: 10.1111/jnc.13619.

29.

Reduced hnRNPA3 increases C9orf72 repeat RNA levels and dipeptide-repeat protein deposition.

Mori K, Nihei Y, Arzberger T, Zhou Q, Mackenzie IR, Hermann A, Hanisch F; German Consortium for Frontotemporal Lobar Degeneration; Bavarian Brain Banking Alliance, Kamp F, Nuscher B, Orozco D, Edbauer D, Haass C.

EMBO Rep. 2016 Sep;17(9):1314-25. doi: 10.15252/embr.201541724. Epub 2016 Jul 26.

30.

Cerebrospinal fluid sTREM2 levels are associated with gray matter volume increases and reduced diffusivity in early Alzheimer's disease.

Gispert JD, Suárez-Calvet M, Monté GC, Tucholka A, Falcon C, Rojas S, Rami L, Sánchez-Valle R, Lladó A, Kleinberger G, Haass C, Molinuevo JL.

Alzheimers Dement. 2016 Dec;12(12):1259-1272. doi: 10.1016/j.jalz.2016.06.005. Epub 2016 Jul 14.

PMID:
27423963
31.

TREM2 deficiency reduces the efficacy of immunotherapeutic amyloid clearance.

Xiang X, Werner G, Bohrmann B, Liesz A, Mazaheri F, Capell A, Feederle R, Knuesel I, Kleinberger G, Haass C.

EMBO Mol Med. 2016 Sep 1;8(9):992-1004. doi: 10.15252/emmm.201606370. Print 2016 Sep.

32.

Immunomodulatory drugs disrupt the cereblon-CD147-MCT1 axis to exert antitumor activity and teratogenicity.

Eichner R, Heider M, Fernández-Sáiz V, van Bebber F, Garz AK, Lemeer S, Rudelius M, Targosz BS, Jacobs L, Knorn AM, Slawska J, Platzbecker U, Germing U, Langer C, Knop S, Einsele H, Peschel C, Haass C, Keller U, Schmid B, Götze KS, Kuster B, Bassermann F.

Nat Med. 2016 Jul;22(7):735-43. doi: 10.1038/nm.4128. Epub 2016 Jun 13.

PMID:
27294876
33.

Impaired protein degradation in FTLD and related disorders.

Götzl JK, Lang CM, Haass C, Capell A.

Ageing Res Rev. 2016 Dec;32:122-139. doi: 10.1016/j.arr.2016.04.008. Epub 2016 May 7. Review.

PMID:
27166223
34.

Generation and deposition of Aβ43 by the virtually inactive presenilin-1 L435F mutant contradicts the presenilin loss-of-function hypothesis of Alzheimer's disease.

Kretner B, Trambauer J, Fukumori A, Mielke J, Kuhn PH, Kremmer E, Giese A, Lichtenthaler SF, Haass C, Arzberger T, Steiner H.

EMBO Mol Med. 2016 May 2;8(5):458-65. doi: 10.15252/emmm.201505952. Print 2016 May.

35.

Automated Spatial Brain Normalization and Hindbrain White Matter Reference Tissue Give Improved [(18)F]-Florbetaben PET Quantitation in Alzheimer's Model Mice.

Overhoff F, Brendel M, Jaworska A, Korzhova V, Delker A, Probst F, Focke C, Gildehaus FJ, Carlsen J, Baumann K, Haass C, Bartenstein P, Herms J, Rominger A.

Front Neurosci. 2016 Feb 29;10:45. doi: 10.3389/fnins.2016.00045. eCollection 2016.

36.

sTREM2 cerebrospinal fluid levels are a potential biomarker for microglia activity in early-stage Alzheimer's disease and associate with neuronal injury markers.

Suárez-Calvet M, Kleinberger G, Araque Caballero MÁ, Brendel M, Rominger A, Alcolea D, Fortea J, Lleó A, Blesa R, Gispert JD, Sánchez-Valle R, Antonell A, Rami L, Molinuevo JL, Brosseron F, Traschütz A, Heneka MT, Struyfs H, Engelborghs S, Sleegers K, Van Broeckhoven C, Zetterberg H, Nellgård B, Blennow K, Crispin A, Ewers M, Haass C.

EMBO Mol Med. 2016 May 2;8(5):466-76. doi: 10.15252/emmm.201506123. Print 2016 May.

37.

Specific Inhibition of β-Secretase Processing of the Alzheimer Disease Amyloid Precursor Protein.

Ben Halima S, Mishra S, Raja KMP, Willem M, Baici A, Simons K, Brüstle O, Koch P, Haass C, Caflisch A, Rajendran L.

Cell Rep. 2016 Mar 8;14(9):2127-2141. doi: 10.1016/j.celrep.2016.01.076. Epub 2016 Feb 25.

38.

Small-Animal PET Imaging of Tau Pathology with 18F-THK5117 in 2 Transgenic Mouse Models.

Brendel M, Jaworska A, Probst F, Overhoff F, Korzhova V, Lindner S, Carlsen J, Bartenstein P, Harada R, Kudo Y, Haass C, Van Leuven F, Okamura N, Herms J, Rominger A.

J Nucl Med. 2016 May;57(5):792-8. doi: 10.2967/jnumed.115.163493. Epub 2016 Feb 11.

39.

Glial Activation and Glucose Metabolism in a Transgenic Amyloid Mouse Model: A Triple-Tracer PET Study.

Brendel M, Probst F, Jaworska A, Overhoff F, Korzhova V, Albert NL, Beck R, Lindner S, Gildehaus FJ, Baumann K, Bartenstein P, Kleinberger G, Haass C, Herms J, Rominger A.

J Nucl Med. 2016 Jun;57(6):954-60. doi: 10.2967/jnumed.115.167858. Epub 2016 Feb 18.

40.

Monomethylated and unmethylated FUS exhibit increased binding to Transportin and distinguish FTLD-FUS from ALS-FUS.

Suárez-Calvet M, Neumann M, Arzberger T, Abou-Ajram C, Funk E, Hartmann H, Edbauer D, Kremmer E, Göbl C, Resch M, Bourgeois B, Madl T, Reber S, Jutzi D, Ruepp MD, Mackenzie IR, Ansorge O, Dormann D, Haass C.

Acta Neuropathol. 2016 Apr;131(4):587-604. doi: 10.1007/s00401-016-1544-2. Epub 2016 Feb 19.

PMID:
26895297
41.

Reduced secretion and altered proteolytic processing caused by missense mutations in progranulin.

Kleinberger G, Capell A, Brouwers N, Fellerer K, Sleegers K, Cruts M, Van Broeckhoven C, Haass C.

Neurobiol Aging. 2016 Mar;39:220.e17-26. doi: 10.1016/j.neurobiolaging.2015.12.014. Epub 2015 Dec 29.

PMID:
26811050
42.

[Mechanisms of Alzheimer's disease : Neuronal hyperactivity and hypoactivity as new therapeutic targets].

Busche MA, Staufenbiel M, Willem M, Haass C, Förstl H.

Nervenarzt. 2016 Nov;87(11):1163-1174. Review. German.

PMID:
26781314
43.

DNA methylation changes in plasticity genes accompany the formation and maintenance of memory.

Halder R, Hennion M, Vidal RO, Shomroni O, Rahman RU, Rajput A, Centeno TP, van Bebber F, Capece V, Garcia Vizcaino JC, Schuetz AL, Burkhardt S, Benito E, Navarro Sala M, Javan SB, Haass C, Schmid B, Fischer A, Bonn S.

Nat Neurosci. 2016 Jan;19(1):102-10. doi: 10.1038/nn.4194. Epub 2015 Dec 14.

PMID:
26656643
44.

Proteolytic Processing of Neuregulin 1 Type III by Three Intramembrane-cleaving Proteases.

Fleck D, Voss M, Brankatschk B, Giudici C, Hampel H, Schwenk B, Edbauer D, Fukumori A, Steiner H, Kremmer E, Haug-Kröper M, Rossner MJ, Fluhrer R, Willem M, Haass C.

J Biol Chem. 2016 Jan 1;291(1):318-33. doi: 10.1074/jbc.M115.697995. Epub 2015 Nov 16.

45.

Investigating the role of filamin C in Belgian patients with frontotemporal dementia linked to GRN deficiency in FTLD-TDP brains.

Janssens J, Philtjens S, Kleinberger G, Van Mossevelde S, van der Zee J, Cacace R, Engelborghs S, Sieben A, Banzhaf-Strathmann J, Dillen L, Merlin C, Cuijt I, Robberecht C, Schmid B, Santens P, Ivanoiu A, Vandenbulcke M, Vandenberghe R, Cras P, De Deyn PP, Martin JJ, Maudsley S, Haass C, Cruts M, Van Broeckhoven C; Belgian Neurology (BELNEU) consortium.

Acta Neuropathol Commun. 2015 Nov 10;3:68. doi: 10.1186/s40478-015-0246-7.

46.

An amyloid-like cascade hypothesis for C9orf72 ALS/FTD.

Edbauer D, Haass C.

Curr Opin Neurobiol. 2016 Feb;36:99-106. doi: 10.1016/j.conb.2015.10.009. Epub 2015 Nov 8. Review.

47.

Monitoring of chronic γ-secretase modulator treatment by serial amyloid-PET.

Brendel M, Jaworska A, Herms J, Trambauer J, Rötzer C, Gildehaus FJ, Carlsen J, Cumming P, Bylund J, Luebbers T, Bartenstein P, Steiner H, Haass C, Baumann K, Rominger A.

Mol Psychiatry. 2015 Oct;20(10):1141. doi: 10.1038/mp.2015.146. No abstract available.

PMID:
26401838
48.

η-Secretase processing of APP inhibits neuronal activity in the hippocampus.

Willem M, Tahirovic S, Busche MA, Ovsepian SV, Chafai M, Kootar S, Hornburg D, Evans LD, Moore S, Daria A, Hampel H, Müller V, Giudici C, Nuscher B, Wenninger-Weinzierl A, Kremmer E, Heneka MT, Thal DR, Giedraitis V, Lannfelt L, Müller U, Livesey FJ, Meissner F, Herms J, Konnerth A, Marie H, Haass C.

Nature. 2015 Oct 15;526(7573):443-7. doi: 10.1038/nature14864. Epub 2015 Aug 31.

PMID:
26322584
49.

Massachusetts Alzheimer's Disease Research Center: progress and challenges.

Hyman BT, Growdon JH, Albers MW, Buckner RL, Chhatwal J, Gomez-Isla MT, Haass C, Hudry E, Jack CR Jr, Johnson KA, Khachaturian ZS, Kim DY, Martin JB, Nitsch RM, Rosen BR, Selkoe DJ, Sperling RA, St George-Hyslop P, Tanzi RE, Yap L, Young AB, Phelps CH, McCaffrey PG.

Alzheimers Dement. 2015 Oct;11(10):1241-5. doi: 10.1016/j.jalz.2015.06.1887. Epub 2015 Aug 19. No abstract available.

50.

Inhibition of amyloid-β plaque formation by α-synuclein.

Bachhuber T, Katzmarski N, McCarter JF, Loreth D, Tahirovic S, Kamp F, Abou-Ajram C, Nuscher B, Serrano-Pozo A, Müller A, Prinz M, Steiner H, Hyman BT, Haass C, Meyer-Luehmann M.

Nat Med. 2015 Jul;21(7):802-7. doi: 10.1038/nm.3885. Epub 2015 Jun 22.

PMID:
26099047

Supplemental Content

Support Center